Press Resease

Dexamethasone Market by Formulation type (liquid, Tablet, Solution for injection, Other), by Patient type (Adult, Pediatric, and Geriatric), by Application (Anti-inflammatory and immunosuppressant effects, Respiratory Distress Syndrome, COVID-19, and Others), and End user (Hospitals, Clinics, Pharmacy & Drug Stores, and Online Pharmacies) – Global Industry Perspective Comprehensive Analysis and Forecast, 2020-2026

Published Date: 06-Aug-2020 Category: Pharmaceutical Report Format : PDF Pages: 135 Report Code: ZMR-5369 Status : Published

The rise of dexamethasone as a lifesaving treatment for critically ill COVID-19 patients due to a sudden outburst, Increasing various inflammatory conditions, and growing prevalence of diseases will act as major driving factors in the growth of global Dexamethasone market.

Description

The report covers forecast and analysis for the Dexamethasone market on a global and regional level. The study provides historic data from 2016 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Billion). The study includes drivers and restraints for the Dexamethasone market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Dexamethasone market on a global as well as regional level.

In order to give the users of this report a comprehensive view on the Dexamethasone market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Formulation type, Patient type, Application, End user, and regional segments are benchmarked based on their market size, growth rate and general attractiveness.

Dexamethasone Market

The report provides company market share analysis in order to give a broader overview of the key players in the Dexamethasone market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the Dexamethasone market on global and regional basis.

The report segments global Dexamethasone market as follows:

Global Dexamethasone Market: Formulation type

  • Liquid
  • Tablet
  • Solution for injection
  • Other

Global Dexamethasone Market: By Patient type

  • Adult
  • Pediatric
  • Geriatric

Global Dexamethasone Market: By Application

  • Anti-inflammatory and immunosuppressant effects
  • Respiratory Distress Syndrome
  • COVID-19
  • Others

Global Dexamethasone Market: By End user

  • Hospitals
  • Clinics
  • Pharmacy & Drug Stores
  • Online Pharmacies

Global Dexamethasone Market: By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Dexamethasone Market, 2016 - 2026, (USD Billion)
    • 2.2. Dexamethasone Market: Snapshot
  • Chapter 3. Global Dexamethasone Market – Industry Analysis
    • 3.1. Dexamethasone Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. The rise of dexamethasone as a lifesaving treatment for critically ill COVID-19 patients due to a sudden outburst
      • 3.2.2. Increasing various inflammatory conditions
      • 3.2.3. Growing prevalence of diseases
    • 3.3. Restraints
      • 3.3.1. Side effects associated with use of Dexamethasone
    • 3.4. Opportunity
      • 3.4.1. High investment in research and development in Dexamethasone market
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by Formulation type segment
      • 3.6.2. Market attractiveness analysis by Patient type segment
      • 3.6.3. Market attractiveness analysis by Application segment
      • 3.6.4. Market attractiveness analysis by End user segment
      • 3.6.5. Market attractiveness analysis by regional segment
  • Chapter 4. Global Dexamethasone Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Dexamethasone market: company market share analysis, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Dexamethasone Market – Formulation Type Segment Analysis
    • 5.1. Global Dexamethasone market overview: by Formulation Type
      • 5.1.1. Global Dexamethasone market revenue share, by Formulation Type, 2019 and 2026
    • 5.2. liquid
      • 5.2.1. Global Dexamethasone market by liquid, 2016-2026 (USD Billion)
    • 5.3. Tablet
      • 5.3.1. Global Dexamethasone market by Tablet, 2016-2026 (USD Billion)
    • 5.4. Sulution for injection
      • 5.4.1. Global Dexamethasone market by Sulution for injection, 2016-2026 (USD Billion)
    • 5.5. Other
      • 5.5.1. Global Dexamethasone market by Other, 2016-2026 (USD Billion)
  • Chapter 6. Global Dexamethasone Market – Patient type Segment Analysis
    • 6.1. Global Dexamethasone market overview: by Patient type
      • 6.1.1. Global Dexamethasone market revenue share, by Patient type, 2019 and 2026
    • 6.2. Growth Factors
      • 6.2.1. Global Dexamethasone market by Growth Factors, 2016-2026 (USD Billion)
    • 6.3. Adult
      • 6.3.1. Global Dexamethasone market by Adult, 2016-2026 (USD Billion)
    • 6.4. Pediatric
      • 6.4.1. Global Dexamethasone market by Pediatric, 2016-2026 (USD Billion)
    • 6.5. Geriatric
      • 6.5.1. Global Dexamethasone market by Geriatric, 2016-2026 (USD Billion)
  • Chapter 7. Global Dexamethasone Market – Application Segment Analysis
    • 7.1. Global Dexamethasone market overview: by Application
      • 7.1.1. Global Dexamethasone market revenue share, by Application, 2019 and 2026
    • 7.2. Growth Factors
      • 7.2.1. Global Dexamethasone market by Growth Factors, 2016-2026 (USD Billion)
    • 7.3. Anti-inflammatory and immunosuppressant effects
      • 7.3.1. Global Dexamethasone market by Anti-inflammatory and immunosuppressant effects, 2016-2026 (USD Billion)
    • 7.4. Respiratory Distress Syndrome
      • 7.4.1. Global Dexamethasone market by Respiratory Distress Syndrome, 2016-2026 (USD Billion)
    • 7.5. COVID-19
      • 7.5.1. Global Dexamethasone market by COVID-19, 2016-2026 (USD Billion)
    • 7.6. Others
      • 7.6.1. Global Dexamethasone market by Others-19, 2016-2026 (USD Billion)
  • Chapter 8. Global Dexamethasone Market – End user Segment Analysis
    • 8.1. Global Dexamethasone market overview: by End user
      • 8.1.1. Global Dexamethasone market revenue share, by End user, 2019 and 2026
    • 8.2. Hospitals
      • 8.2.1. Global Dexamethasone market by Hospitals, 2016-2026 (USD Billion)
    • 8.3. Clinics
      • 8.3.1. Global Dexamethasone market by Clinics, 2016-2026 (USD Billion)
    • 8.4. Pharmacy & Drug Stores
      • 8.4.1. Global Dexamethasone market by Pharmacy & Drug Stores, 2016-2026 (USD Billion)
    • 8.5. Online Pharmacies
      • 8.5.1. Global Dexamethasone market by Online Pharmacies, 2016-2026 (USD Billion)
  • Chapter 9. Global Dexamethasone Market - Regional Analysis
    • 9.1. Global Dexamethasone market overview: by region
      • 9.1.1. Global Dexamethasone market revenue share, by region, 2019 and 2026
    • 9.2. North America
      • 9.2.1. North America Dexamethasone market, by country, 2016-2026 (USD Billion)
      • 9.2.2. North America Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
      • 9.2.3. North America Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
      • 9.2.4. North America Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
      • 9.2.5. North America Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.2.6. The U.S.
        • 9.2.6.1. The U.S. Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.2.6.2. The U.S. Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.2.6.3. The U.S. Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.2.6.4. The U.S. Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.2.7. Rest of North America
        • 9.2.7.1. Rest of North America Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.2.7.2. Rest of North America Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.2.7.3. Rest of North America Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.2.7.4. Rest of North America Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
    • 9.3. Europe
      • 9.3.1. Europe Dexamethasone market, by country, 2016-2026 (USD Billion)
      • 9.3.2. Europe Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
      • 9.3.3. Europe Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
      • 9.3.4. Europe Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
      • 9.3.5. Europe Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.3.6. U.K.
        • 9.3.6.1. U.K. Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.3.6.2. U.K. Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.3.6.3. U.K. Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.3.6.4. U.K. Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.3.7. France
        • 9.3.7.1. France Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.3.7.2. France Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.3.7.3. France Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.3.7.4. France Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.3.8. Germany
        • 9.3.8.1. Germany Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.3.8.2. Germany Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.3.8.3. Germany Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.3.8.4. Germany Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.3.9. Rest of Europe
        • 9.3.9.1. Rest of Europe Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.3.9.2. Rest of Europe Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.3.9.3. Rest of Europe Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.3.9.4. Rest of Europe Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific Dexamethasone market, by country, 2016-2026 (USD Billion)
      • 9.4.2. Asia Pacific Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
      • 9.4.3. Asia Pacific Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
      • 9.4.4. Asia Pacific Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
      • 9.4.5. Asia Pacific Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.4.6. China
        • 9.4.6.1. China Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.4.6.2. China Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.4.6.3. China Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.4.6.4. China Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.4.7. Japan
        • 9.4.7.1. Japan Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.4.7.2. Japan Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.4.7.3. Japan Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.4.7.4. Japan Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.4.8. India
        • 9.4.8.1. India Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.4.8.2. India Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.4.8.3. India Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.4.8.4. India Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.4.9. Rest of Asia Pacific
        • 9.4.9.1. Rest of Asia Pacific Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.4.9.2. Rest of Asia Pacific Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.4.9.3. Rest of Asia Pacific Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.4.9.4. Rest of Asia Pacific Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
    • 9.5. Latin America
      • 9.5.1. Latin America Dexamethasone market, by country, 2016-2026 (USD Billion)
      • 9.5.2. Latin America Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
      • 9.5.3. Latin America Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
      • 9.5.4. Latin America Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
      • 9.5.5. Latin America Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.5.6. Brazil
        • 9.5.6.1. Brazil Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.5.6.2. Brazil Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.5.6.3. Brazil Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.5.6.4. Brazil Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
      • 9.5.7. Rest of Latin America
        • 9.5.7.1. Rest of Latin America Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
        • 9.5.7.2. Rest of Latin America Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
        • 9.5.7.3. Rest of Latin America Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
        • 9.5.7.4. Rest of Latin America Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
    • 9.6. Middle East & Africa
      • 9.6.1. Middle East & Africa Dexamethasone market, 2016-2026 (USD Billion)
      • 9.6.2. Middle East & Africa Dexamethasone market revenue, by Formulation Type, 2016-2026 (USD Billion)
      • 9.6.3. Middle East & Africa Dexamethasone market revenue, by Patient type, 2016-2026 (USD Billion)
      • 9.6.4. Middle East & Africa Dexamethasone market revenue, by Application, 2016-2026 (USD Billion)
      • 9.6.5. Middle East & Africa Dexamethasone market revenue, by End user, 2016-2026 (USD Billion)
  • Chapter 10. Company Profiles
    • 10.1. Cadila Healthcare Ltd.
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product Portfolio
      • 10.1.4. Business Strategy
      • 10.1.5. Recent Developments
    • 10.2. Wockhardt Ltd
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Product Portfolio
      • 10.2.4. Business Strategy
      • 10.2.5. Recent Developments
    • 10.3. Fresenius Kabi
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Product Portfolio
      • 10.3.4. Business Strategy
      • 10.3.5. Recent Developments
    • 10.4. Dwarkesh Pharmaceuticals Private Limited
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Product Portfolio
      • 10.4.4. Business Strategy
      • 10.4.5. Recent Developments
    • 10.5. Schwitz Biotech
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Product Portfolio
      • 10.5.4. Business Strategy
      • 10.5.5. Recent Developments
    • 10.6. Lexine Technochem Private Limited
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Product Portfolio
      • 10.6.4. Business Strategy
      • 10.6.5. Recent Developments
    • 10.7. Mapro Lifescience
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Product Portfolio
      • 10.7.4. Business Strategy
      • 10.7.5. Recent Developments
    • 10.8. Therawin Formulations
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Product Portfolio
      • 10.8.4. Business Strategy
      • 10.8.5. Recent Developments
    • 10.9. Shervotec Pharmaceuticals
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Product Portfolio
      • 10.9.4. Business Strategy
      • 10.9.5. Recent Developments
    • 10.10. Therawin Formulations
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Product Portfolio
      • 10.10.4. Business Strategy
      • 10.10.5. Recent Developments
    • 10.11. Acichem Laboratories
      • 10.11.1. Overview
      • 10.11.2. Financials
      • 10.11.3. Product Portfolio
      • 10.11.4. Business Strategy
      • 10.11.5. Recent Developments
    • 10.12. Quality Nexgen Pharmaceuticals Pvt Ltd
      • 10.12.1. Overview
      • 10.12.2. Financials
      • 10.12.3. Product Portfolio
      • 10.12.4. Business Strategy
      • 10.12.5. Recent Developments
    • 10.13. Kern Pharma SL
      • 10.13.1. Overview
      • 10.13.2. Financials
      • 10.13.3. Product Portfolio
      • 10.13.4. Business Strategy
      • 10.13.5. Recent Developments
    • 10.14. Symbiotic Pharma
      • 10.14.1. Overview
      • 10.14.2. Financials
      • 10.14.3. Product Portfolio
      • 10.14.4. Business Strategy
      • 10.14.5. Recent Developments
    • 10.15. AuroMedics
      • 10.15.1. Overview
      • 10.15.2. Financials
      • 10.15.3. Product Portfolio
      • 10.15.4. Business Strategy
      • 10.15.5. Recent Developments

Methodology


Frequently Asked Questions

North America will be the leading region during the forecast period. Increasing cases of covid-19, and High prevalence of diseases, will boost the market growth in this region. Europe will be the second largest market.

Industry Players of Dexamethasone Market are Cadila Healthcare Ltd., Wockhardt Ltd., Dwarkesh Pharmaceuticals Private Limited, Schwitz Biotech, Lexine Technochem Private Limited, Mapro Lifescience, Therawin Formulations, Shervotec Pharmaceuticals, Acichem Laboratories, Quality Nexgen Pharmaceuticals Pvt Ltd ,Kern Pharma SL, Symbiotic Pharma, AuroMedics, Fresenius Kabi, Hikma, Mylan, Somerset Therapeutics, American Regent, Shanghai General Pharmaceutical, Hunan Hansen Pharm, Chengdu Brilliant Pharmaceutical, Cisen Pharmaceutical, CSPC Group, Jiangsu Wuzhong Pharm, Guangzhou Baiyunshan Tianxin Pharmaceutical among others.

The rise of dexamethasone as a lifesaving treatment for critically ill COVID-19 patients due to a sudden outburst, Increasing various inflammatory conditions, and growing prevalence of diseases will act as major driving factors in the growth of global Dexamethasone market.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social